Antiviral Drugs - Asia

Asia

The revenue in the Antiviral Drugs market in Asia is estimated to reach €8.55bn in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 2.36%, leading to a market volume of €9.61bn by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue of €28,420.00m in 2024.
In Asia, Japan leads the market for antiviral drugs with its advanced pharmaceutical industry and high demand for influenza treatments.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Antiviral Drugs market in Asia has been steadily growing over the past few years.

Customer preferences: Customers in Asia are increasingly looking for antiviral drugs that are effective against a wide range of viruses. They are also interested in drugs that have minimal side effects, are easy to administer, and are affordable.

Trends in the market: In China, the market for antiviral drugs has been growing rapidly due to the outbreak of COVID-19. The demand for drugs such as remdesivir and favipiravir has skyrocketed, leading to shortages and price hikes. In Japan, there has been a shift towards the development of new antiviral drugs that are effective against emerging viruses such as dengue and Zika. South Korea has also seen an increase in demand for antiviral drugs due to the outbreak of MERS in 2015.

Local special circumstances: In India, the market for antiviral drugs is highly fragmented due to the presence of a large number of small and medium-sized pharmaceutical companies. These companies often focus on producing generic drugs that are affordable for the domestic market. In contrast, the market in Japan is dominated by large pharmaceutical companies that invest heavily in research and development.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in Asia can be attributed to several underlying macroeconomic factors. These include the increasing prevalence of viral diseases, rising healthcare expenditure, and growing awareness about the benefits of antiviral drugs. Additionally, the COVID-19 pandemic has highlighted the importance of antiviral drugs and accelerated the development of new treatments. Overall, the Antiviral Drugs market in Asia is expected to continue growing in the coming years as countries invest in research and development and seek to improve healthcare outcomes for their populations.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.